These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6985855)

  • 1. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin.
    Dasgupta A; Crossey MJ
    Am J Med Sci; 1997 Feb; 313(2):75-9. PubMed ID: 9030671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous accumulation products and serum protein binding in uremia.
    McNamara PJ; Lalka D; Gibaldi M
    J Lab Clin Med; 1981 Nov; 98(5):730-40. PubMed ID: 7299243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.
    Shoeman DW; Azarnoff DL
    Pharmacology; 1972; 7(3):169-77. PubMed ID: 5054587
    [No Abstract]   [Full Text] [Related]  

  • 9. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
    Dasgupta A; Volk A
    Ther Drug Monit; 1996 Jun; 18(3):284-7. PubMed ID: 8738769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of guanidino substances from uremic plasma on insulin binding to erythrocyte receptors in uremia.
    Rocić B; Breyer D; Granić M; Milutinović S
    Horm Metab Res; 1991 Oct; 23(10):490-4. PubMed ID: 1761280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of valproic acid on the serum protein binding of lorazepam and diazepam.
    Calvo R; Carlos R; Erill S
    Int J Clin Pharmacol Res; 1986; 6(3):213-5. PubMed ID: 3091512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein binding of valproic acid in uremic patients.
    Bruni J; Wang LH; Marbury TC; Lee CS; Wilder BJ
    Neurology; 1980 May; 30(5):557-9. PubMed ID: 6768007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein carbamylation and decreased acidic drug protein binding in uremia.
    Erill S; Calvo R; Carlos R
    Clin Pharmacol Ther; 1980 May; 27(5):612-8. PubMed ID: 7371359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment.
    Nikolaev V; Sarnatskaya V; von Appen K; Ivanov A; Rotellar E; Haspar M; Klinkmann H
    Artif Organs; 1996 Jan; 20(1):17-23. PubMed ID: 8645124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein binding of thiopental in patients with impaired renal or hepatic function.
    Ghoneim MM; Pandya H
    Anesthesiology; 1975 May; 42(5):545-9. PubMed ID: 1130720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased plasma protein binding of diazoxide in uremia.
    O'Malley K; Velasco M; Pruitt A; McNay JL
    Clin Pharmacol Ther; 1975 Jul; 18(1):53-8. PubMed ID: 1149362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of adsorbing materials for uremic blood purification.
    Denti E
    Biomater Med Devices Artif Organs; 1974; 2(3):295-300. PubMed ID: 4458819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.